All
EC Approves Novartis’ Kymriah CAR-T Cell Therapy
August 28th 2018The European Commission (EC) has approved Novartis’ chimeric antigen receptor T cell (CAR-T) cell therapy Kymriah for the treatment of B-cell acute lymphoblastic leukemia and relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
FDA Says No Need to Compound from Bumetanide, Nicardipine hydrochloride, and Vasopressin
August 27th 2018FDA proposed in a Federal Register notice that bumetanide, nicardipine hydrochloride, and vasopressin should not be included on the list of bulk drug substances that outsourcing facilities may use in compounding.